Schwab Charles Investment Management Inc. decreased its holdings in Natus Medical Inc (NASDAQ:BABY) by 7.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 149,741 shares of the medical equipment provider’s stock after selling 12,821 shares during the period. Schwab Charles Investment Management Inc. owned 0.48% of Natus Medical worth $5,721,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. SG Americas Securities LLC bought a new stake in Natus Medical during the 3rd quarter valued at $138,000. Sei Investments Co. lifted its position in Natus Medical by 149.9% during the 3rd quarter. Sei Investments Co. now owns 7,952 shares of the medical equipment provider’s stock worth $298,000 after acquiring an additional 4,770 shares during the period. Crossmark Global Holdings Inc. acquired a new stake in Natus Medical during the 3rd quarter worth about $315,000. Capital Management Associates NY acquired a new stake in Natus Medical during the 3rd quarter worth about $412,000. Finally, DekaBank Deutsche Girozentrale acquired a new stake in Natus Medical during the 3rd quarter worth about $444,000. 95.76% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts have weighed in on BABY shares. BidaskClub upgraded Natus Medical from a “strong sell” rating to a “sell” rating in a research note on Tuesday, March 6th. Roth Capital set a $39.00 target price on Natus Medical and gave the stock a “buy” rating in a report on Tuesday, February 27th. Zacks Investment Research cut Natus Medical from a “buy” rating to a “hold” rating in a report on Tuesday, December 26th. William Blair cut Natus Medical from an “outperform” rating to a “market perform” rating in a report on Monday, January 8th. Finally, Benchmark reissued a “buy” rating and issued a $49.00 target price (down previously from $55.00) on shares of Natus Medical in a research report on Tuesday, January 16th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. Natus Medical currently has an average rating of “Hold” and an average target price of $44.33.
In other news, Director Ken Ludlum sold 4,000 shares of the firm’s stock in a transaction that occurred on Friday, March 2nd. The shares were sold at an average price of $31.68, for a total transaction of $126,720.00. Following the completion of the transaction, the director now directly owns 93,825 shares of the company’s stock, valued at approximately $2,972,376. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 5.50% of the company’s stock.
BABY stock traded up $1.10 during midday trading on Wednesday, reaching $34.90. 88,675 shares of the company’s stock traded hands, compared to its average volume of 569,567. The company has a quick ratio of 2.54, a current ratio of 3.32 and a debt-to-equity ratio of 0.37. Natus Medical Inc has a one year low of $28.00 and a one year high of $43.60. The firm has a market capitalization of $1,087.66, a P/E ratio of -56.16 and a beta of 0.55.
Natus Medical (NASDAQ:BABY) last announced its earnings results on Wednesday, February 7th. The medical equipment provider reported $0.42 earnings per share for the quarter, missing the consensus estimate of $0.54 by ($0.12). Natus Medical had a positive return on equity of 11.36% and a negative net margin of 4.05%. The business had revenue of $131.40 million for the quarter, compared to analyst estimates of $131.38 million. During the same quarter last year, the company posted $0.51 EPS. Natus Medical’s quarterly revenue was up 22.0% on a year-over-year basis. sell-side analysts anticipate that Natus Medical Inc will post 1.63 earnings per share for the current year.
Natus Medical declared that its Board of Directors has authorized a share buyback plan on Thursday, February 22nd that authorizes the company to repurchase $30.00 million in outstanding shares. This repurchase authorization authorizes the medical equipment provider to buy shares of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s leadership believes its shares are undervalued.
COPYRIGHT VIOLATION WARNING: This piece was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/21/schwab-charles-investment-management-inc-cuts-position-in-natus-medical-inc-baby.html.
Natus Medical Company Profile
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.